Alfonso Giovanni Recordare

Andrea Porzionato

Andromachi Kotsafti

Angelo Paolo Dei Tos

Anna Pozza

Antonio Scapinello

Astghik Stepanyan

Barbara Di Camillo

Boris Franzato

Cesare Ruffolo

Cesco Cava

Chiara Cipollari

Chiara Romiti

Chiara Vignotto

Federico Scognamiglio

Francesca Bergamo

Francesco Marchegiani

Gaya Spolverato

Gianluca Businello

Giorgio Rivella

Giovanni Bordignon

Giovanni Pirozzolo

Giulia Becherucci

Giulia Capelli

Giuseppe Portale

Ignazio Castagliuolo

imerio angriman

Isacco Maretto

Ivana Cataldo

Luca Dal Santo

Luca Facci

Marco Agostini

Marco Massani

Marco Scarpa

Matteo Fassan

Melania Scarpa

Michela Campi

Ottavia De Simoni

Pierluigi Pilati

Roberta Salmaso

Roberto Merenda

Romeo Bardini

Salvatore Pucciarelli

Silvia Negro

Silvio Guerriero

Stefano Brignola

Tommaso Stecca

Valentina Chiminazzo

Vincenza Guzzardo

Vittorina Zagonel

Zizzo Maurizio

Background: 

Studies evaluating sex differences in colorectal cancer (CRC) tumor microenvironment are limited, and no previous study has focused on rectal cancer patients’ constitutive immune surveillance mechanisms. The authors aimed to assess gender-related differences in the immune microenvironment of rectal cancer patients.
Methods: 

A systematic review and meta-analysis were conducted up to 31 May 2021, including studies focusing on gender-related differences in the CRC tumor microenvironment. Data on the mutational profile of rectal cancer were extracted from the Cancer Genome Atlas (TCGA). A subanalysis of the two IMMUNOREACT trials (NCT04915326 and NCT04917263) was performed, aiming to detect gender-related differences in the immune microenvironment of the healthy mucosa in patients with early (IMMUNOREACT 1 cohort) and locally advanced rectal cancer following neoadjuvant therapy (IMMUNOREACT 2 cohort). In the retrospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 442 patients (177 female and 265 male), while in the retrospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), we enrolled 264 patients (80 female and 184 male). In the prospective IMMUNOREACT 1 cohort (therapy naive), the authors enrolled 72 patients (26 female and 46 male), while in the prospective IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy), the authors enrolled 105 patients (42 female and 63 male).
Results: 

Seven studies reported PD-L1 expression in the CRC microenvironment, but no significant difference could be identified between the sexes. In the TGCA series, mutations of SYNE1 and RYR2 were significantly more frequent in male patients with rectal cancer. In the IMMUNOREACT 1 cohort, male patients had a higher expression of epithelial cells expressing HLA class I, while female patients had a higher number of activated CD4+Th1 cells. Female patients in the IMMUNOREACT 2 cohort showed a higher infiltration of epithelial cells expressing CD86 and activated cytotoxic T cells (P=0.01).
Conclusions: 

Male patients have more frequent oncogene mutations associated with a lower expression of T-cell activation genes. In the healthy mucosa of female patients, more Th1 cells and cytotoxic T cells suggest a potentially better immune response to the tumor. Sex should be considered when defining the treatment strategy for rectal cancer patients or designing prognostic scores

Archivio istituzionale della ricerca - Università di Padova

English

IMMUNOREACT 5:  female patients with rectal cancer have better immune editing mechanisms than male patients, a cohort study

IMMUNOREACT 5: female patients with rectal cancer have better immune editing mechanisms than male patients, a cohort study

Abstract

Similar works

Full text

Available Versions

Archivio istituzionale della ricerca - Università di Padova